Skip to main content

Advertisement

SpringerLink
Log in

Initial trabeculectomy with 5-fluorouracil with or without subconjunctival bevacizumab in the management of pseudoexfoliation glaucoma

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the outcomes of trabeculectomy with 5-fluorouracil (5-FU) with or without subconjunctival bevacizumab in the surgical management of pseudoexfoliation glaucoma (PXG).

Methods

This retrospective study consisted of 49 cases with PXG who underwent initial trabeculectomy with 5-FU. The cases were divided into two age- and sex-matched groups. In 23 cases, subconjunctival bevacizumab was injected (1.25 mg/0.05 mL) at the end of the surgery and in 26 of them the surgery was performed without bevacizumab. The groups were evaluated for the postoperative differences of the intraocular pressure (IOP) and the number of the anti-glaucomatous medications. Independent t, Kolmogorov–Smirnov and Chi square tests were used for statistical analysis.

Results

The mean preoperative IOP was 30.91 ± 4.50 mmHg under the mean number of 2.4 ± 0.7 drops in bevacizumab group. The IOP decreased to 10.22 ± 2.63 mmHg (first week), 10.91 ± 1.88 mmHg (first month), 12.35 ± 2.5 mmHg (3rd month), 12.65 ± 2.35 mmHg (sixth month) and 12.7 ± 1.9 mmHg at the final visit. The mean preoperative IOP was 31.27 ± 5.60 mmHg under the mean number of 2.3 ± 0.7 drops in without bevacizumab group. The IOP decreased to 10.08 ± 2.59 mmHg (first week), 11.00 ± 1.87 mmHg (first month), 12.81 ± 2.04 (3rd month), 13.62 ± 2.21 mmHg (sixth month) and 12.9 ± 2.4 mmHg at the final visit. In both groups, IOP reduced significantly postoperatively. There were no significant differences between the preoperative and the postoperative IOP values.

Conclusion

The additional benefit of single dose of intraoperative bevacizumab was not observed in trabeculectomy with 5-FU in PXG.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Aboobakar IF, Johnson WM, Stamer WD, Hauser MA, Allingham RR (2017) Major review: exfoliation syndrome; advances in disease genetics, molecular biology, and epidemiology. Exp Eye Res 154(1):88–103

    Article  CAS  PubMed  Google Scholar 

  2. Anastasopoulos E, Founti P, Topouzis F (2015) Update on pseudoexfoliation syndrome pathogenesis and associations with intraocular pressure, glaucoma and systemic diseases. Curr Opin Ophthalmol 26(2):82–89

    Article  PubMed  Google Scholar 

  3. Lim SH, Cha SC (2017) Long-term outcomes of mitomycin-C trabeculectomy in exfoliative glaucoma versus primary open-angle glaucoma. J Glaucoma 26(4):303–310

    Article  PubMed  Google Scholar 

  4. Cabourne Clarke JC, Schlottmann PG, Evans JR (2015) Mitomycin C versus 5-fluorouracil for wound healing in glaucoma surgery. Cochrane Database Syst Rev 6(11):CD006259. https://doi.org/10.1002/14651858.cd006259.pub2

    Article  Google Scholar 

  5. De Fendi LI, Arruda GV, Scott IU, Paula JS (2013) Mitomycin C versus 5-fluorouracil as an adjunctive treatment for trabeculectomy: a meta-analysis of randomized clinical trials. Clin Exp Ophthalmol 41(8):798–806

    Article  PubMed  Google Scholar 

  6. Shin HJ, Kim SN, Chung H, Kim TE, Kim HC (2016) Intravitreal anti-vascular endothelial growth factor therapy and retinal nerve fiber layer loss in eyes with age-related macular degeneration: a meta-analysis. Invest Ophthalmol Vis Sci 57(4):1798–1806

    Article  CAS  PubMed  Google Scholar 

  7. Lanzetta P, Loewenstein A (2017) Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol 255(7):1259–1273

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Li Z, Van Bergen T, Van de Veire S, Van de Vel I, Moreau H, Dewerchin M, Maudgal PC, Zeyen T, Spileers W, Moons L, Stalmans I (2009) Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci 50(11):5217–5225

    Article  PubMed  Google Scholar 

  9. Cheng JW, Cheng SW, Wei RL, Lu GC (2016) Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery. Cochrane Database Syst Rev 15(1):CD009782. https://doi.org/10.1002/14651858.cd009782

    Article  Google Scholar 

  10. Park HY, Kim JH, Park CK (2013) VEGF induces TGF-β1 expression and myofibroblast transformation after glaucoma surgery. Am J Pathol 182(6):2147–2154

    Article  CAS  PubMed  Google Scholar 

  11. Kong DH, Kim MR, Jang JH, Na HJ, Lee S (2017) A review of anti-angiogenic targets for monoclonal antibody cancer therapy. Int J Mol Sci 18(8):E1786. https://doi.org/10.3390/ijms18081786

    Article  CAS  PubMed  Google Scholar 

  12. The AGIS Investigators (2000) The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130(4):429–440

    Article  Google Scholar 

  13. Yuki K, Shiba D, Kimura I, Ohtake Y, Tsubota K (2009) Trabeculectomy with or without intraoperative sub-tenon injection of triamcinolone acetonide in treating secondary glaucoma. Am J Ophthalmol 147(6):1055–1060

    Article  CAS  PubMed  Google Scholar 

  14. Esson DW, Popp MP, Liu L, Schultz GS, Sherwood MB (2004) Microarray analysis of the failure of filtering blebs in a rat model of glaucoma filtering surgery. Invest Ophthalmol Vis Sci 45(12):4450–4462

    Article  PubMed  Google Scholar 

  15. Ozgonul C, Mumcuoglu T, Gunal A (2014) The effect of bevacizumab on wound healing modulation in an experimental trabeculectomy model. Curr Eye Res 39(5):451–459

    Article  CAS  PubMed  Google Scholar 

  16. Kiddee W, Orapiriyakul L, Kittigoonpaisan K, Tantisarasart T, Wangsupadilok B (2015) Efficacy of adjunctive subconjunctival bevacizumab on the outcomes of primary trabeculectomy with mitomycin C: a prospective randomized placebo-controlled trial. J Glaucoma 24(8):600–606

    Article  PubMed  PubMed Central  Google Scholar 

  17. Suh W, Kee C (2013) The effect of bevacizumab on the outcome of trabeculectomy with 5-fluorouracil. J Ocul Pharmacol Ther 29(7):646–651

    Article  CAS  PubMed  Google Scholar 

  18. Freiberg FJ, Matlach J, Grehn F, Karl S, Klink T (2013) Postoperative subconjunctival bevacizumab injection as an adjunct to 5-fluorouracil in the management of scarring after trabeculectomy. Clin Ophthalmol 7:1211–1217

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Akkan JU, Cilsim S (2015) Role of subconjunctival bevacizumab as an adjuvant to primary trabeculectomy: a prospective randomized comparative 1-year follow-up study. J Glaucoma 24(1):1–8

    Article  PubMed  Google Scholar 

  20. Tai TY, Moster MR, Pro MJ, Myers JS, Katz JC (2015) Needle bleb revision with bevacizumab and mitomycin C compared with mitomycin C alone for failing filtration blebs. J Glaucoma 24(4):311–315

    Article  PubMed  Google Scholar 

  21. Simsek T, Cankaya AB, Elgin U (2012) Comparison of needle revision with subconjunctival bevacizumab and 5-fluorouracil injection of failed trabeculectomy blebs. J Ocul Pharmacol Ther 28(5):542–546

    Article  CAS  PubMed  Google Scholar 

  22. Paula JS, Ribeiro VR, Chahud F, Cannellini R, Monteiro TC, Gomes EC, Reinach PS, Rodrigues Mde L, Silva-Cunha A (2013) Bevacizumab-loaded polyurethane subconjunctival implants: effects on experimental glaucoma filtration surgery. J Ocul Pharmacol Ther 29(6):566–573

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Health Sciences, Ulucanlar Eye Education and Research Hospital, Ulucanlar caddesi No:59, 06240, Altindag, Ankara, Turkey

    Ufuk Elgin, Emine Sen, Salih Çolak & Pelin Yılmazbas

Authors
  1. Ufuk Elgin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emine Sen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Salih Çolak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pelin Yılmazbas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ufuk Elgin.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest related to this manuscript.

Ethical approval

Our presentation was approved by Ethics Committee of Numune Training and Research Hospital. All of the study procedures were conducted in accordance with the Declaration of Helsinki, and informed consents were taken from all of the participants. This manuscript was presented in European Society of Cataract and Refractive Surgery Congress, Lisbon, 2017 as a presented poster.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elgin, U., Sen, E., Çolak, S. et al. Initial trabeculectomy with 5-fluorouracil with or without subconjunctival bevacizumab in the management of pseudoexfoliation glaucoma. Int Ophthalmol 39, 1211–1217 (2019). https://doi.org/10.1007/s10792-018-0926-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-018-0926-y

Keywords

Search

Navigation